Edwards Lifesciences Corp <EW.N>: UBS Assumes Coverage With Buy vs Neutral Rating; Target Price $110 vs $90
EW•Related News
XPLR Infrastructure Q2 FY26 net income falls 51.9% to $38 million; revenue rises 6.1% to $363 million
XIFR•
Vestis sets fiscal Q3 earnings release, conference call and webcast
VSTS•
Federal Signal declares quarterly dividend of $0.15 per share
FSS•
Cadence Design Systems Inc <CDNS.O>: Rosenblatt Securities raises target price to $420 from $410
CDNS•
Boeing posts larger-than-expected Q2 loss as Air Force One costs rise
BA•